TPIV200/huFR-1: Phase II started

TapImmune and AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) began an open-label, U.S. Phase II trial to evaluate intradermal TPIV200 on day 1 of each 4-week cycle for the first 6 cycles plus IV d...